

medicina

BUENOS AIRES VOL. 78 Supl. III - 2018



medicina

BUENOS AIRES, VOL. 78 Supl. III - 2018

COMITÉ DE REDACCIÓN

Héctor O. Alonso
Instituto Cardiovascular Rosario, Santa Fe, Argentina

Pablo J. Azurmendi
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Damasia Becú Villalobos
*Instituto de Biología y Medicina Experimental-CONICET,
Buenos Aires, Argentina*

José H. Casabé
*Instituto de Cardiología y Cirugía Cardiovascular,
Hospital Universitario Fundación Favaloro,
Buenos Aires, Argentina*

María Marta de Elizalde de Bracco
*IMEX-CONICET-Academia Nacional de Medicina,
Buenos Aires, Argentina*

Eduardo L. De Vito
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Guillermo Jaim Etcheverry *Facultad
de Medicina, UBA, Argentina*

Isabel Narvaiz Kantor
Organización Panamericana de la Salud (OPS/OMS), Argentina

Basilio A. Kotsias
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Gustavo Kusminsky
Hospital Universitario Austral, Buenos Aires, Argentina

Isabel A. Lüthy
*Instituto de Biología y Medicina Experimental (IBYME),
Buenos Aires, Argentina*

Daniel A. Manigot
Hospital San Juan de Dios, Buenos Aires, Argentina

Jorge A. Manni
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Rodolfo S. Martin
*Facultad de Ciencias Biomédicas y
Hospital Universitario Austral, Buenos Aires, Argentina*

Guillermo D. Mazzolini
*Instituto de Investigaciones en Medicina Traslacional-CONICET,
Hospital Universitario Austral, Buenos Aires, Argentina*

Christiane Dosne Pasqualini
Academia Nacional de Medicina, Buenos Aires, Argentina

Rodolfo C. Puche
*Facultad de Ciencias Médicas, Universidad Nacional de
Rosario, Santa Fe, Argentina*

Viviana Ritacco
*Instituto Nacional de Enfermedades Infecciosas ANLIS-CONICET,
Buenos Aires, Argentina*

Guillermo B. Semeniuk
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

La Tapa (Ver p xx)
Los palos rosas, 2015
Daniela Kantor

MEDICINA (Buenos Aires) – Revista bimestral – ISSN 0025-7680 (Impresa) – ISSN 1669-9106 (En línea)

REVISTA BIMESTRAL

Registro de la Propiedad Intelectual N° 5350968
Personería Jurídica N° C-7497

Publicación de la Fundación Revista Medicina (Buenos Aires)

Propietario de la publicación: **Fundación Revista Medicina**

Queda hecho el depósito que establece la Ley 11723

Publicada con el apoyo del Ministerio de Ciencia, Tecnología e Innovación Productiva.

MEDICINA no tiene propósitos comerciales. El objeto de su creación ha sido propender al adelanto de la medicina argentina.

Los beneficios que pudieran obtenerse serán aplicados exclusivamente a este fin.

Aparece en MEDLINE (PubMed), ISI-THOMSON REUTERS (Journal Citation Report, Current Contents, Biological Abstracts, Biosis, Life Sciences), CABI (Global Health), ELSEVIER (Scopus, Embase, Excerpta Medica), SciELO, LATININDEX, BVS (Biblioteca Virtual en Salud), DOAJ, Google Scholar y Google Books.

Incluida en el Núcleo Básico de Revistas Científicas Argentinas del CONICET.

Directores Responsables:

Basilio A. Kotsias, Damasias Becú Villalobos, Isabel Narvaiz Kantor, Guillermo B. Semeniuk

Secretaría de Redacción: Ethel Di Vita, Instituto de Investigaciones Médicas Alfredo Lanari, Combatientes de Malvinas 3150,
1427 Buenos Aires, Argentina
Tel. 5287-3827 Int. 73919 y 4523-6619
e-mail: revmedbuenosaires@gmail.com – http://www.medicinabuenosaires.com

Vol. 78, Supl.III, Noviembre
2018

Edición realizada por

Diseño y Diagramación: Andrés Esteban Zapata - aez.sgi@gmail.com - 11 5509 2767
Impreso en PQC - Berón de Astrada 2064 - C.A.B.A. - 4919 1702

REUNIÓN CONJUNTA SAIC SAI SAFIS 2018

**LXIII REUNIÓN ANUAL DE LA
SOCIEDAD ARGENTINA DE INVESTIGACIÓN CLÍNICA (SAIC)**

**LXVI REUNIÓN ANUAL DE LA
SOCIEDAD ARGENTINA DE INMUNOLOGÍA (SAI)**

**REUNIÓN ANUAL DE LA
SOCIEDAD ARGENTINA DE FISIOLOGÍA (SAFIS)**

**CON LA PARTICIPACIÓN DE
SOCIEDAD ARGENTINA DE VIROLOGÍA (SAV)
ASOCIACIÓN ARGENTINA DE NANOMEDICINAS (NANOMED-ar)**

**14-17 de noviembre de 2018
Hotel 13 de Julio – Mar del Plata**

EDITORES RESPONSABLES

Claudia Pérez Leirós
Pablo Baldi
Alberto Crottogini

JOINT MEETING SAIC SAI SAFIS 2018

**LXIII ANNUAL MEETING OF
SOCIEDAD ARGENTINA DE INVESTIGACIÓN CLÍNICA (SAIC)**

**LXVI ANNUAL MEETING OF
SOCIEDAD ARGENTINA DE INMUNOLOGÍA (SAI)**

**ANNUAL MEETING OF
SOCIEDAD ARGENTINA DE FISIOLOGÍA (SAFIS)**

**WITH THE PARTICIPATION OF
SOCIEDAD ARGENTINA DE VIROLOGÍA (SAV)
ASOCIACIÓN ARGENTINA DE NANOMEDICINAS (NANOMED-ar)**

**November 14-17, 2018
Hotel 13 de Julio – Mar del Plata**

RESPONSIBLE EDITORS

**Claudia Pérez Leirós
Pablo Baldi
Alberto Crottogini**

LA TAPA

Los palos rosas, 2015

Daniela Kantor

Técnica: Acrílico sobre bastidor. Medidas: 35 x 70 cm

Daniela Kantor es diseñadora gráfica (FADU-UBA), historietista, ilustradora y pintora. Desde 2014 es docente en la materia Ilustración, cátedra Roldán, FADU, y da talleres para niños (Filbita 2017, taller de comics librerías Matilda-Tigre, taller de historietas CCK, etc.) Estudió con el maestro Alberto Breccia dibujo de historieta y con Carlos Gorriarena realizó el Curso de color. Asistió al Taller de acuarela y pastel de Carlos Nine y realizó clínicas de pintura con Mariano Sapia y Tulio de Sagastizábal. Además de ilustrar muchos libros para niños y adolescentes (Editoriales Troquel, Abran Cancha, Puerto de Palos, Santillana, etc.), es parte de la revista de historietas El tripero, publica en revistas (Barcelona, Zona de obras, Crisis, suplemento Ñ, entre otras). Publicó su primera novela gráfica: Mujer primeriza (2014). Su proyecto de segundo libro de historietas Naturalella obtuvo la primera mención del Premio Nueva Historieta Argentina (2016) y fue publicado en parte en Dis-tinta, el compilado de Liniers y Martín Pérez (Ed. Sudamericana, 2016). Expone sus pinturas desde 2003; recientemente exhibió en Cic.edu.ar

Instagram: Daniela.kantor.9

www.kantorconk.blogspot.com

www.danikantor.portfoliobox.net

CONSEJOS DIRECTIVOS

SAIC

Presidente
Claudia Pérez Leirós

Vicepresidente
Mónica Costas

Secretaria
Flavia Saravia

Tesorera
Daniela Vittori

Prosecretaria
Gabriela Marino

Vocales
Bruno Buchholz
Jimena Cabilla
Cintia Eliana Citterio
Alejandro Curino
Walter Fornes
María Noel Galardo
Yanina Langle
Gabriela Lombardi
Vanina Medina
Liliana Monasterolo
Analía Reinés
Nora Saraco
Carmen Stanganelli

Revisores de cuentas
Ruth Rosenstein
Pablo Azurmendi

SAI

Presidente
Pablo Baldi

Vicepresidente
Gladis Susana Álvarez

Secretaria
Marisa Mariel Fernández

Tesorero
Daniel González Maglio

Pro-Secretaria
María Susana Salva

Pro-Tesorera
María Victoria Delpino

Vocales
Belkys Maletto
Paula Carasi
Ana Rosa Pérez
Luciana Balboa
Gisela Seminario
Mercedes Fuertes
Alejandra Goldman
Federico Jensen

SAFIS

Presidente
Alberto Crottogini

Vicepresidente
María Cecilia Larocca

Secretaria
Elena Lascano

Tesorero
Juan Gabriel Barra

Vocales Titulares
Luján Alvarez
Daniela Olea
Martín Vila Petroff
María Celeste Villa Abrille

Vocales Suplentes
Valeria Rivarola
Roxana Toriano

**Vocal Región Litoral
Noreste**
Silvina Villanueva

Vocal Región Cuyo
Emiliano Diez

Vocal Región Centro
Ana Macchione

**Vocal Región Litoral
Noroeste**
Susana Jerez

Vocal Región Sur
Marta Elena Roque

Vocales Externos
Carolina Garciarena
Guillermo L. Lehmann

Órgano de fiscalización
Paola Locatelli
Carlos Valverde

LAS SOCIEDADES QUE ORGANIZAN ESTA REUNIÓN CONJUNTA

AGRADECEN EL APOYO DE

INSTITUCIONES OFICIALES

CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS

MINISTERIO DE CIENCIA, TECNOLOGÍA E INNOVACIÓN PRODUCTIVA

AGENCIA NACIONAL DE PROMOCIÓN CIENTÍFICA Y TECNOLÓGICA

OTRAS INSTITUCIONES Y AUSPICIANTES

FUNDACIÓN CHERNY

FUNDACIÓN HONORIO BIGAND

PREMIO EDUARDO SOTO EN NEUROCIENCIAS

PREMIO IRENE FARYNA DE RAVEGLIA

FAMILIA CAMILIÓN DE HURTADO

FUNDACIÓN ARGENTINA DE NANOTECNOLOGÍA

AMERICAN SOCIETY FOR MICROBIOLOGY

INTERNATIONAL SOCIETY FOR NEUROIMMUNOMODULATION

SOCIETY FOR MUCOSAL IMMUNOLOGY

EMBO

THE COMPANY OF BIOLOGISTS

LAS SOCIEDADES QUE ORGANIZAN ESTA REUNIÓN CONJUNTA

AGRADECEN LA COLABORACIÓN DE LAS SIGUIENTES

EMPRESAS Y AUSPICIANTES

ANALITICAL TECH

APBIOTECH

BIOCIENTIFICA SA

BIODYNAMICS SRL

BRISTOL-MYERS SQUIBB

CIENTIST

DIAGNOSMED

EMBIOTEC

ETC INTERNACIONAL

GADOR

INBIO

LAB SYSTEMS

LOBOV

MICROLAT

MIGLIORE LACLAUSTRA

NOVARTIS

SARTORIUS

TECNOLAB

THERMOFISHER

PALABRAS DE BIENVENIDA

Estimados colegas y amigos,

Nos complace darles la bienvenida a la Reunión Conjunta SAIC SAI SAFIS 2018 de la **Sociedad Argentina de Investigación Clínica (SAIC)**, la **Sociedad Argentina de Inmunología (SAI)** y la **Sociedad Argentina de Fisiología (SAFIS)**, que este año también cuenta con la participación de la **Sociedad Argentina de Virología (SAV)** y la **Asociación Argentina de Nanomedicinas (NANOMED-ar)**.

El Programa Científico es abarcador y cubre los aspectos más sobresalientes e innovadores de las diferentes disciplinas. Contamos con la presencia de investigadores argentinos y extranjeros de la mayor jerarquía internacional que expondrán los avances de su trabajo en conferencias y simposios. Además, se han inscripto más de 760 trabajos de estudiantes de doctorado, becarios, investigadores, médicos residentes y otros profesionales del ámbito de la Salud con los últimos resultados de sus investigaciones, los que serán expuestos en forma de comunicaciones orales y pósters. Se han seleccionado algunos de estos trabajos para su presentación en simposios para favorecer el intercambio con los pares extranjeros. Asimismo, Jurados de expertos han pre-seleccionado trabajos para competir por distintos premios: se otorgarán los Premios León Cherny al mejor trabajo multidisciplinario, Honorio Bigand al mejor proyecto presentado por investigadores jóvenes, Eduardo Soto al mejor trabajo en Neurociencias, Irene Faryna de Raveglia en Oncología, Leonardo Satz en Inmunología, SAFIS Jóvenes Investigadores en Fisiología, Camillón de Hurtado en Fisiopatología Cardiovascular y César Milstein en Enfermedad de Chagas. Se otorgará un premio de la American Society for Microbiologists en el área de Infectología y Menciones a los mejores pósters por áreas de la SAIC. Estos premios constituyen un estímulo para los grupos de investigación argentinos que mejoran la calidad de sus trabajos año tras año y se otorgan merced al generoso aporte de las fundaciones Cherny, Bigand, de la Dra Pasquini, de la Familia Camillón de Hurtado y de las empresas ETC Internacional y Novartis Argentina SA. Habrá también minicursos, encuentros con expertos y exposición comercial.

El principal objetivo de esta Reunión Conjunta es ofrecer a los asistentes el marco académico propicio para alentar la interacción entre científicos argentinos y con pares extranjeros que investigan las bases moleculares y bioquímicas de las enfermedades humanas. Nuestras sociedades reúnen a investigadores y académicos de las distintas ramas de la Biomedicina, con un importante enfoque en la medicina traslacional. Desde la organización alentamos la discusión y formación científica en un clima de intercambio cordial y multidisciplinario.

Aprovechamos la oportunidad para agradecer a las comisiones directivas de las sociedades participantes quienes, en un año de crecientes complicaciones económicas y de funcionamiento, han trabajado con enorme dedicación y responsabilidad para el éxito de esta Reunión. Nuestro agradecimiento a las instituciones oficiales y no gubernamentales que apoyaron la organización de este evento a través de subsidios u otros aportes; a las empresas y entidades que auspiciaron y acompañan con su presencia este Congreso; a las empresas organizadoras y a la gerencia del Hotel 13 de Julio por su amabilidad y profesionalismo.

Esperamos que disfruten de este encuentro en sus aspectos científicos y académicos como también en salidas sociales aprovechando las instalaciones turísticas de esta espléndida ciudad de Mar del Plata.

Dra. Claudia Pérez Leirós
Presidente SAIC

Dr. Pablo Baldi
Presidente SAI

Dr. Alberto Crottogini
Presidente SAFIS

WELCOME WORDS

We are pleased to welcome you to the SAIC SAI SAFIS 2018 Joint Meeting, organized by Sociedad Argentina de Investigación Clínica (SAIC), Sociedad Argentina de Inmunología (SAI) and Sociedad Argentina de Fisiología (SAFIS), with the participation of Sociedad Argentina de Virología (SAV) and Asociación Argentina de Nanomedicinas (NANOMED-ar).

The scientific program is comprehensive, spanning the most glowing and innovative aspects of the diverse fields. Outstanding international experts from Argentina and from abroad will discuss their recent advances in the setting of conferences and symposia. In addition, PhD and postdoctoral fellows, young investigators, resident physicians and other health professionals will address the recent results of their research in over 760 communications during poster and oral sessions. A number of these works have been selected for presentation in symposia, in order to foster interactions of their authors with foreign colleagues. Likewise, expert juries have pre-selected communications to compete for the following awards: The León Cherny Award to the best multidisciplinary research, The Honorio Bigand Award to the best project presented by young investigators, The Eduardo Soto Award to the best research in Neuroscience, The Irene Faryna de Raveglia Award in Oncology, The Leonardo Satz Award in Immunology, The SAFIS Young Investigators in Physiology Award, The Camilión de Hurtado Award in Cardiovascular Pathophysiology and The César Milstein Award in Chagas Disease. A Prize in the field of Infectology from The American Society for Microbiology, as well as Mentions from SAIC to the best posters, will also be awarded. These awards convey a motivation to the Argentine research groups that progressively improve the quality of their investigations, and are granted thanks to the generosity of the Cherny and Bigand Foundations, Dr. Pasqualini, the Camilión de Hurtado Family and the companies ETC Internacional y Novartis Argentina SA. Minicourses, Meeting with the Expert Sessions and a commercial exhibit will also take place during the Joint Meeting.

The main goal of this Joint Meeting is providing the attendees with an appropriate academic framework to encourage interactions between Argentine scientists and colleagues from abroad who investigate the molecular and biochemical bases of human ailments. The members from our societies are investigators and academics from diverse biomedical areas with a strong focus in translational medicine. From the Organizing Committee, we firmly encourage scientific discussion and training in an atmosphere of warm, multidisciplinary interaction.

We take advantage of this opportunity to thank the Boards of the participating Societies which, in a year of increasing economic and managing complications have worked with enormous commitment and responsibility for the success of this Meeting. Our gratitude, as well, to the official and private institutions that supported the organization of this event with grants or other financial contributions; to the sponsoring and organizing companies and entities; and to the staff of 13 de Julio Hotel for their kindness and professionalism.

We wholeheartedly hope that you enjoy this Meeting in its scientific, academic and social aspects, while profiting the attractions of this beautiful, splendid Mar del Plata.

Dr. Claudia Pérez Leirós
SAIC President

Dr. Pablo Baldi
SAI President

Dr. Alberto Crottogini
SAFIS President

Intake of groundwater with endocrine disruptors is a risk for exposed populations. Amphibian larvae are very sensitive to compounds with thyroid disruptor action. Objectives: Evaluate antagonistic effect of iodine on the action of groundwater contaminated with thyroid-disrupting substances, in the metamorphosis of amphibians by means of a bioassay of chronic toxicity. *Xenopus Laevis* larvae were used immersed in water: a) filtered network as control (C) (n=5), b) groundwater of 30-meter depth of the Glew city with aggregate of iodine (6.7gr/l) (ANI) (n=8) and c) groundwater without iodine (AN) (n=8). After 69 days of exposure, the morphological assessment was performed by determining weight, height and stages of metamorphosis (premetamorphosis, prometamorphosis and climax) according to the Nieuwkoop and Faber criteria. The statistical analysis was performed with the Fisher and Tukey tests. The weight and final size did not differ between the groups. The metamorphosis was completed in 100% of the C, 60% of the ANI (p<0.0001) and 42.8% of the AN (p<0.0001), observing difference between the experimental groups (p<0.02). The total time of metamorphosis was higher in AN (67 ± 1.5) vs. C (55 ± 1) and ANI (51 ± 0.6) (p<0.02). The premetamorphosis time was higher in AN vs. ANI (p<0.05), being similar in C and AN. The duration of prometamorphosis it was: C: 24 ± 2 days, ANI: 25 ± 2.1 days, AN: 36 ± 0.5 (p<0.0001). The morphological changes, dependent on thyroid hormones, caused by the groundwater are reversed with iodine; suggesting a possible antagonistic effect on the iodine transporter of the substances present in the water of the study zone.

553. (384) CHARACTERIZATION OF EXTRACELLULAR VESICLES RELEASED BY TRIIODOTHYRONINE-STIMULATED MICE DENDRITIC CELLS (DCS): ROL IN PARACRINE DC ACTIVATION

Dana María Negretti Borge, Rocío del Carmen Bravo Miana, Florencia Soler, Giusiano Lucila, Ana Lucía De Paul, Ana Carolina Donadio, María del Mar Montesinos, Claudia Pellizas *Facultad de Ciencias Químicas, Centro de Investigación en Bioquímica Clínica e Inmunología (CIBICI)*

We provided evidence of triiodothyronine (T3) stimulation of mice dendritic cells (DCs), driving pro-inflammatory and cytotoxic responses, exploited in an antitumor DC-based vaccination protocol. Extracellular Vesicles (EVs) exhibit a crucial role in cellular communication and EVs secreted by DCs (EVs-DCs) may be involved in the amplification of the immune response. Our aim was to characterize the populations of EVs-DCs and assess their role in paracrine DC communication after T3 exposition. Immature bone marrow DCs (iDC) were obtained from WT C57BL/6 mice and stimulated (or not) with T3 (5nM-18h, DCs-T3). Secreted EVs-DCs from iDCs and DCs-T3 (EVs-DCs-T3) were isolated by differential ultracentrifugation at 2,000g (2K, large EVs); 10,000g (10k, Microvesicles); and 100,000g (100K, small EVs: sEVs). Morphological analysis of EVs was conducted by Transmission Electron Microscopy (TEM) and dynamic light scattering (DLS), and molecular characterization of EVs by western blot analysis (CD63 and CD81). A functional assay evaluated the syngeneic DC profile induced by treatment with EVs-DCs-T3 (markers of DC maturation: MHCII, CD86, and CD40, Flow Cytometry-FACS; and IL-12, FACS and ELISA). Statistical analysis: ANOVA-SNK. Data obtained from TEM analysis of the different fractions from both, iDCs and DCs-T3, showed the presence of secreted EVs. Size profile analysis revealed a significant higher frequency of 150-600 nm for 2K and 10K, whereas 100k exhibited more than 90% (p<0.01) of EVs sized 30-150 nm (sEVs). DLS analysis showed a similar pattern. Besides, sEVs secreted by DCs-T3 significantly increased the expression of DC phenotypic maturation markers, and the production and secretion of IL-12. This study allowed the morphological characterization of EVs populations secreted by mice DCs that in turn induced the activation of syngeneic iDCs, endowing these cells with a Th1-type driving phenotype that may be involved in the adaptive response induced by T3 exposition to DCs.

554. (318) ACTIVINS AND PROLACTINOMA DEVELOPMENT I. GENDER DIFFERENCES

Erika Faraoni, Agustina Marcial, Alejandra Abeledo Machado,

Maria Andrea Camilletti, Susana Rulli, Graciela Díaz-Torga *Instituto de Biología y Medicina Experimental (IBYME - CO-NICET)*

Activins are members of the transforming growth factor beta (TGFβ) family of proteins. They are homodimers composed of βA subunits (activin A) or βB subunits (activin B). Besides their known function on pituitary gonadotrophs, activins also modulate lactotroph population, being inhibitors of cell proliferation and prolactin secretion. Its inhibitory function is modulated by inhibins and follistatin (FST). Up today, the role of activins in prolactinoma development remains unknown. We propose that alterations in the pituitary activin-inhibin system (Ac-In) are involved in prolactinoma development. In this work, we studied the pituitary expression (mRNA by RTqPCR) of Ac-In components in two experimental models of prolactinoma: mice deficient in dopamine receptor type 2 (Drd2 -/-) and mice over-expressing the β subunit of human chorionic gonadotropin (hCGβ+). These animal models present sex differences: an increase in the pituitary size and hyperprolactinemia are observed only in adult female transgenic mice, but not in males. We found that pituitaries from Drd2-/- and hCGβ+ females (prolactinomas) present decreased expression of several components of Ac-In system: βA and βB subunits, and activin receptors (ActRII, ActRI), concomitant with an increase in FST expression (activin antagonist). On the other hand, male pituitaries (both mice models) present higher expression of Ac-In components compared to females, without genotype differences. According to these results, we postulate that: 1- As activins are inhibitors of lactotroph function, a decreased expression of Ac-In system (βA, βB, receptors), concomitant with an increase in FST expression, is involved in prolactinoma development in transgenic female mice (Drd2-/- and hCGβ+); 2- The higher expression of Ac-In system found in male pituitaries (absence of adenoma), could be protecting this sex from prolactinoma development.

555. (320) ACTIVINS AND PROLACTINOMA DEVELOPMENT II. EFFECTS OF AN OVARECTOMY

Erika Faraoni, Alejandra Abeledo Machado, Agustina Marcial, *Maria Andrea Camilletti*, Susana Rulli, Graciela Díaz-Torga *Instituto de Biología y Medicina Experimental (IBYME - CO-NICET)*

It was previously shown that an ovariectomy (OVX) prevents pituitary hyperplasia in Drd2-/- and hCGβ+ female mice, indicating the participation of ovarian factors in the development of prolactinoma. However, a hormone replacement with estradiol after OVX does not restore tumor development. These results suggest the participation of other ovarian factors. In this work, we propose that gonadal inhibins are involved in the development of these pituitary tumors. Inhibins and activins are members of the TGFβ family of proteins. Activins are homodimers composed of βA subunits (activin A) or βB subunits (activin B). Inhibins are heterodimeric proteins composed of a α subunit and a β subunit (βA or βB), giving rise to inhibin A (α-βA) or inhibin B (α-βB). Gonadal secreted inhibins antagonize, in the pituitary, the activin inhibitory function on lactotroph population. We postulate that an OVX, induces alterations in the pituitary activin-inhibin system (Ac-In), preventing prolactinoma development. Results: Pituitaries from adult Drd2-/- and hCGβ+ female mice (prolactinomas) show a reduced mRNA expression (analyzed by RTqPCR) of the Ac-In system components (βA and βB subunits, ActRI and ActRII receptors) when compared with WT counterpart. On the contrary, when Drd2-/- and hCGβ+ female mice are ovariectomized at 2-month-old, they do not develop prolactinoma in the adulthood, and the pituitary expression of Ac-In system remains similar to those expressed in WT counterpart. According to these results we postulate that, after OVX, the decline in circulating inhibins restores the pituitary activin inhibitory-function on lactotroph population, preventing the development of prolactinoma.

556. (629) PRL-1 EXPRESSION IN A PROLACTINOMA EXPERIMENTAL MODEL: A POSSIBLE ROLE IN THE TUMORAL DEVELOPMENT

Gabriela Moyano Crespo, Carolina Guido, Pablo Pérez, Laura Cecenaro, Florencia Picech, Juan Pablo Petiti, Alicia Ines